Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
molindone (SPN-810)
print preview
bookmark
share with colleague
General Information
Company
Supernus Pharmaceuticals Inc.
Description
Extended-release formulation of molindone, an antipsychotic
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase II
Indication
Attention deficit hyperactivity disorder (ADHD)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information